LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8
Antibodies, Bispecific
/ immunology
Antigens, CD
/ immunology
Humans
Immunotherapy
/ methods
Leukocyte Immunoglobulin-like Receptor B1
/ antagonists & inhibitors
Lymphocyte Activation
/ drug effects
Neoplasms
/ immunology
T-Lymphocyte Subsets
/ immunology
T-Lymphocytes, Cytotoxic
/ immunology
Tumor Cells, Cultured
Journal
Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R
Informations de publication
Date de publication:
15 08 2019
15 08 2019
Historique:
received:
05
11
2018
accepted:
10
06
2019
pubmed:
30
6
2019
medline:
10
4
2020
entrez:
30
6
2019
Statut:
ppublish
Résumé
Elicitation of tumor cell killing by CD8
Identifiants
pubmed: 31253728
pii: jimmunol.1801472
doi: 10.4049/jimmunol.1801472
pmc: PMC6680066
doi:
Substances chimiques
Antibodies, Bispecific
0
Antigens, CD
0
LILRB1 protein, human
0
Leukocyte Immunoglobulin-like Receptor B1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1076-1087Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2019 by The American Association of Immunologists, Inc.
Références
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Blood. 2018 Jan 18;131(3):311-322
pubmed: 29122757
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Blood. 2014 Apr 24;123(17):2625-35
pubmed: 24578504
Front Immunol. 2013 Nov 11;4:371
pubmed: 24273543
Cancer Immunol Immunother. 2005 Dec;54(12):1162-71
pubmed: 15889254
Cell Cycle. 2016;15(1):25-40
pubmed: 26636629
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nat Commun. 2017 Jan 16;8:14049
pubmed: 28091601
Nucleic Acids Res. 2009 Oct;37(18):e123
pubmed: 19620212
Immunology. 2004 Aug;112(4):531-42
pubmed: 15270723
Eur J Immunol. 2015 Dec;45(12):3324-38
pubmed: 26426795
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Nat Biotechnol. 2015 Oct;33(10):1079-86
pubmed: 26389576
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Leukemia. 2016 Feb;30(2):484-91
pubmed: 26239198
Science. 2008 Aug 15;321(5891):956-60
pubmed: 18599741
FASEB J. 2010 Mar;24(3):689-99
pubmed: 19841038
Immunol Cell Biol. 2015 Mar;93(3):290-6
pubmed: 25367186
J Immunol. 2004 Dec 15;173(12):7223-9
pubmed: 15585844
Genome Biol. 2014;15(12):550
pubmed: 25516281
Int J Cancer. 2002 Aug 20;100(6):690-7
pubmed: 12209608
Nat Rev Drug Discov. 2023 Jan;22(1):7
pubmed: 36460866
Nat Methods. 2017 Oct;14(10):979-982
pubmed: 28825705
J Immunol. 2016 Feb 1;196(3):947-55
pubmed: 26802060
Cancer Immunol Res. 2016 Mar;4(3):194-203
pubmed: 26787823
Mol Med. 2015 Nov;21(1):782-791
pubmed: 26322846
Immun Ageing. 2009 Aug 28;6:11
pubmed: 19715573
Cancer Immunol Immunother. 2015 Jun;64(6):677-88
pubmed: 25742933
Cancer Res. 2008 Jan 1;68(1):143-51
pubmed: 18172306
J Exp Med. 1999 Apr 5;189(7):1093-100
pubmed: 10190900
Nature. 2018 Dec;564(7735):268-272
pubmed: 30479382
PLoS One. 2015 Oct 28;10(10):e0141669
pubmed: 26510188
Cell. 2017 Jun 15;169(7):1342-1356.e16
pubmed: 28622514
J Immunol. 2003 Dec 15;171(12):6611-20
pubmed: 14662864
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705